UNSPSC 51183803: Voglibose

This classification denotes a glucosidase inhibitor and anti-diabetic agent with the molecular formula C10H21NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S77P977AG8, chemically known as 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol but more generally known as voglibose, which bears US NIH Compound Identifier 5677. European Medicines Agency schedules Voglibose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00085MIG.

UNSPSC 51183803 Voglibose is a Commodity code covering specific oral antidiabetic pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure voglibose and related generic pharmaceuticals through multistate cooperative frameworks that consolidate demand across participating state agencies, counties, cities, and other public facilities, negotiating volume pricing with manufacturers and distributing products through authorized pharmaceutical wholesalers. The scope includes manufacturer supply of products meeting FDA requirements with specific National Drug Codes (NDCs), compliance certifications (cGMP and Drug Supply Chain Security Act compliance), and flexible pricing structures such as flat price, net price, or WAC-minus formats. Issuing bodies under this code include state departments of administration or health, multistate cooperative purchasing alliances, and participating local government entities within those cooperative networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products spanning Minnesota, Oregon, and other participating states. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), carry $5 million commercial general liability insurance, and accept a 3 percent administrative fee. The contract term runs two years for new vendors with optional MMCAP extensions, or aligns with existing agreement expiration through June 30, 2028 for incumbent responders, with award effective July 1, 2026. Evaluation weights 75 percent price competitiveness, 10 percent fixed pricing, and 5 percent each for administrative compliance, EDI capability, and acceptance of the administrative fee structure. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.